Small-cap biotech company Orthocell Ltd [ASX:OCC] has entered a trading halt today. A request that will give them time to announce a fresh capital raise. As it stands we are scant for details.
Aussie biotech Orthocell Ltd [ASX:OCC] has seen a magnificent spike in their share price today, up a whopping 21.5% at time of writing. Results from clinical trials of their core regenerative medical solution CelGro, have led to such spikes in the Orthocell share price throughout 2019, and today is no exception...
Shares of regenerative medicine company Orthocell Ltd [ASX:OCC] have soared in today’s trading, currently up over 11% at time of writing. The biotech small-cap released the final results today of their CelGro clinical trial, which was successfully completed back in May.
The ASX 200 recorded a 1% rise over the last month, the big winner being Lynas Corporation Ltd [ASX:LYC] with a 54% gain. Today we will be looking at what has been driving the best performing stocks on the ASX for May.
Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May .Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward.